Stewart Hallett

Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022.

Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.

Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.

Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Quintiles Capital Solutions (Quintiles Capital) is a venture capital firm founded in 2000. The firm is headquartered in Durham, North Carolina.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Part of Ainsly Ltd., Placid0, Inc. develops a mobile platform for assessing ocular conditions. The company is based in Pasadena, CA. The company was founded in 2020 by Andrew Moshfeghi, Zach Bodnar, Darius M. Moshfeghi, Jochen Kumm, Emmett T. Cunningham. Placid0 was acquired by Ainsly Ltd. on February 10, 2022.

HealthQuest Capital Management Co LLC (HealthQuest Capital) is a private equity firm founded in 2013 by Garheng Kong and Randy L. Scott. The firm is headquartered in Redwood City, California.

Silk Technologies Ltd. develops silk-derived protein (SDP) products for ophthalmic applications. Its patented SDP material is currently being developed as a compound for the treatment of patients with dry eye disease. The company was founded by Brian D. Lawrence and is headquartered in Plymouth, MN.

Pr3vent, Inc provides healthcare technology services. The company was founded by Jochen Kumm and Darius M. Moshfegh and is headquartered in Palo Alto, CA.

NovaQuest Capital Management LLC (NovaQuest Capital Management) is a private equity firm founded in 2010 by John Layton Bradley and Jonathan Edward Tunnicliffe. The firm is headquartered in Raleigh, North Carolina.

California Pacific Medical Center operates medical centers. It offers acute and specialty care services including obstetrics, gynecology, cardiovascular, pediatrics, neurosciences, orthopedics, and organ transplantation. The company is headquartered in San Francisco, CA.

Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA.

Ophthalmology Innovation Summit provides investment services. The private company is based in Jericho. The American company was founded by Emmett T. Cunningham, Gilbert H. Kliman.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Intelligenetics, Inc. engages in the provision of bioinformatics services. The company is headquartered in Campbell, CA.

Part of Quintiles Transnational Corp., IQVIA IES UK Ltd. is a healthcare company that leverages artificial intelligence (AI) and machine learning to help customers address their biggest challenges. The company is based in Reading, UK and was founded in 1995. The British company brings doctors, data scientists, engineers, and researchers together to build practical, scalable solutions. IQVIA solutions powered by AI and machine learning have moved beyond automation and process efficiency to uncover new insights and unlock new opportunities.